---
title: "H.C. Wainwright Reaffirms Their Buy Rating on NervGen Pharma (NGEN)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289477645.md"
description: "H.C. Wainwright analyst Ram Selvaraju reaffirmed a Buy rating on NervGen Pharma (NGEN) with an $18.00 price target, outperforming the market consensus of a Strong Buy with an $11.90 average target. Selvaraju, known for strong performance in the healthcare sector, maintains his bullish stance on the stock."
datetime: "2026-06-11T13:46:14.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289477645.md)
  - [en](https://longbridge.com/en/news/289477645.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289477645.md)
generator: "portal-rs"
---

# H.C. Wainwright Reaffirms Their Buy Rating on NervGen Pharma (NGEN)

H.C. Wainwright analyst Ram Selvaraju maintained a Buy rating on NervGen Pharma on June 8 and set a price target of $18.00.

### Introducing TipRanks MCP for Agents

-   Deliver institutional-grade market data directly into Claude, ChatGPT, Cursor, and other MCP-compatible AI tools.
-   Designed for personal research, portfolio monitoring, and AI-assisted investment workflows.

Selvaraju covers the Healthcare sector, focusing on stocks such as Emergent Biosolutions, Aclaris Therapeutics, and Urogen Pharma. According to TipRanks, Selvaraju has an average return of 16.9% and a 48.51% success rate on recommended stocks. 

The word on The Street in general, suggests a Strong Buy analyst consensus rating for NervGen Pharma with a $11.90 average price target.

### Related Stocks

- [NGEN.US](https://longbridge.com/en/quote/NGEN.US.md)
- [EBS.US](https://longbridge.com/en/quote/EBS.US.md)
- [ACRS.US](https://longbridge.com/en/quote/ACRS.US.md)
- [URGN.US](https://longbridge.com/en/quote/URGN.US.md)

## Related News & Research

- [SoundHound AI (SOUN) On Healthcare Deal Momentum And The Case For A Higher Valuation](https://longbridge.com/en/news/297694466.md)
- [Northland Securities Sticks to Their Buy Rating for Rezolve AI (RZLV)](https://longbridge.com/en/news/297930459.md)
- [Mamdani is putting AI on recess for 600,000 students](https://longbridge.com/en/news/297813637.md)
- [Morgans Remains a Buy on EchoIQ Limited (EIQ)](https://longbridge.com/en/news/297720502.md)
- [Kiniksa Pharma to join Wells Fargo Healthcare Conference fireside chat](https://longbridge.com/en/news/298070883.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**